All the funding deals in the regenerative medicine market
Last updated: 13 July 2026
In our updated market reports, you will find everything you need
The regenerative medicine market is attracting strong investor interest across gene therapy, cell therapy, tissue engineering, regenerative biologics, stem cell therapy, and exosome therapy.
We conducted deep research and collected 70 regenerative medicine funding deals announced between Q1 2024 and Q2 2026.
We refresh this regenerative medicine funding page very often to add new deals and keep the information current.
Insights
- The 70 regenerative medicine funding deals in this list represent about $4.1 billion in disclosed financing between Q1 2024 and Q2 2026.
- Regenerative medicine companies raised about $1.37 billion in the first half of 2026, almost matching the total recorded during the whole of 2025.
- Gene therapy and cell therapy remain the main investment areas, but investors are also supporting manufacturing, tissue engineering, exosomes, and regenerative biologics.
- The largest regenerative medicine deal was Kriya Therapeutics' $320 million Series D, followed by Cellares at $257 million and Serapha Bio at $230 million.
- Six regenerative medicine deals reached at least $150 million, showing that investors still support large rounds for companies with ambitious clinical or manufacturing programs.
- Manufacturing infrastructure is becoming an important part of the regenerative medicine market. Cellares, Celltrio, Kincell Bio, and Limula all raised capital for production technologies or services.
- Eye diseases attracted several major gene therapy rounds, including Beacon Therapeutics, Ray Therapeutics, Restore Vision, and Neuracle Genetics.
- Parkinson's disease remains a major focus for regenerative medicine companies. Aspen Neuroscience, Kenai Therapeutics, and iRegene Therapeutics are developing cell replacement therapies.
- Several companies raised more than once during the period. EpilepsyGTx, Latus Bio, Pelage Pharmaceuticals, and Tr1X returned with larger or additional financing rounds.
- Regenerative medicine funding is expanding beyond human therapeutics. Gallant raised $18 million to develop ready-to-use stem cell therapies for pets.
Summary table of the funding deals for the regenerative medicine market since 2024
We define the regenerative medicine market as therapies and products that repair, replace, or regenerate damaged cells, tissues, or organs.
It includes Cell Therapies, Gene Therapies, Tissue Engineering, Regenerative Biologics, Stem Cell Therapies, and Exosome Therapies.
It excludes broader adjacent markets unless the product is built specifically for this use case.
We focused exclusively on pure players, defined as companies with at least 70–80% of their business directly tied to the regenerative medicine market.
Our analysis has been done at a global level with a minimum funding threshold of $300k.
If you want a longer-term view, we also have a study of how funding activity in the regenerative medicine market has changed over the years.
| Name | What they do | Amount in $ | Quarter | Source(s) |
|---|---|---|---|---|
| Restore Vision | Develops gene therapies for inherited retinal disorders. | $8.9M | Q2 2026 | Restore Vision |
| Ray Therapeutics | Develops optogenetic therapies that aim to restore vision in people with severe retinal degeneration. | $125.0M | Q2 2026 | Ray Therapeutics |
| Omeza Holdings | Develops regenerative wound care products for chronic and difficult-to-heal wounds. | $8.5M | Q2 2026 | Access Newswire |
| Latus Bio | Develops scalable AAV gene therapies for diseases affecting large patient populations. | $97.0M | Q2 2026 | Business Wire |
| CREATE Medicines | Develops in vivo immune programming and CAR-T therapies for autoimmune diseases and cancer. | $122.0M | Q2 2026 | CREATE Medicines |
| Waypoint Bio | Uses spatial biology and artificial intelligence to design cell therapies for solid tumors. | $20.0M | Q2 2026 | BioSpace |
| SonoThera | Uses ultrasound to deliver nonviral genetic medicines for rare diseases. | $125.0M | Q2 2026 | SonoThera |
| FesariusTherapeutics | Develops hydrogel tissue products for skin repair and wound management. | $20.0M | Q2 2026 | PR Newswire |
| Serapha Bio | Develops an in vivo base-editing therapy for alpha-1 antitrypsin deficiency. | $230.0M | Q2 2026 | Boundless Bio IR |
| STRM.BIO | Develops nonviral delivery technology for in vivo cell engineering and gene therapy. | $8.0M | Q1 2026 | PR Newswire |
| MEDIPOST | Develops stem cell therapies made from donated umbilical cord blood. | $140.0M | Q1 2026 | Business Wire |
| Juvena Therapeutics | Develops AI-enabled regenerative biologics designed to restore damaged tissue function. | $33.5M | Q1 2026 | Business Wire |
| Cytotheryx | Develops cell therapies for serious liver diseases. | $60.0M | Q1 2026 | PR Newswire |
| Cellares | Provides automated development and manufacturing services for cell therapies. | $257.0M | Q1 2026 | Cellares News |
| PranaX | Develops exosome-based regenerative biologics for healthy aging and tissue repair. | $17.0M | Q1 2026 | PR Newswire |
| Pandorum Technologies | Develops programmable regenerative therapies based on exosomes and tissue engineering. | $18.0M | Q1 2026 | Business Wire |
| BreezeBio | Develops precision genetic medicines using nanoparticle delivery technology for in vivo cell engineering. | $60.0M | Q1 2026 | BreezeBio |
| Tacit Therapeutics | Develops programmable RNA repair medicines for inherited neurological diseases. | $19.0M | Q1 2026 | Tacit Therapeutics |
| Vyriad | Develops targeted genetic medicines, including an in vivo CAR-T therapy. | $25.0M | Q4 2025 | Vyriad |
| Link Cell Therapies | Develops logic-gated CAR-T cell therapies for blood cancers and solid tumors. | $60.0M | Q4 2025 | PR Newswire |
| EpilepsyGTx | Develops single-dose gene therapies for focal epilepsy and related neurological disorders. | $33.0M | Q4 2025 | Business Wire |
| Morphocell Technologies | Develops engineered liver tissue products for people with severe liver disease. | $50.0M | Q4 2025 | PR Newswire |
| Aspen Neuroscience | Develops personalized cell replacement therapies for Parkinson's disease and other neurological conditions. | $115.0M | Q4 2025 | Aspen Neuroscience |
| Azalea Therapeutics | Develops technology that engineers therapeutic cells directly inside the patient's body. | $82.0M | Q4 2025 | GlobeNewswire |
| Rarity PBC | Develops an autologous gene therapy for the rare immune disorder ADA-SCID. | $4.6M | Q4 2025 | Business Wire |
| Pelage Pharmaceuticals | Develops regenerative treatments that reactivate dormant hair follicle stem cells. | $120.0M | Q4 2025 | Pelage Pharmaceuticals |
| Tr1X | Develops allogeneic regulatory T-cell therapies for autoimmune and inflammatory diseases. | $50.0M | Q4 2025 | BioSpace |
| Trogenix | Develops gene therapies for aggressive solid tumors using its Odysseus platform. | $95.0M | Q4 2025 | Trogenix |
| iRegene Therapeutics | Develops donor-derived cell therapies for Parkinson's disease and retinal degeneration. | $40.0M | Q3 2025 | PR Newswire |
| Kriya Therapeutics | Develops gene therapies for chronic diseases with high unmet medical needs. | $320.0M | Q3 2025 | Kriya Therapeutics |
| Neuracle Genetics | Develops AAV gene therapies for eye and neurological diseases. | $19.0M | Q3 2025 | The Bio News |
| Gameto | Develops stem cell-based reproductive treatments, including technology for maturing eggs outside the body. | $44.0M | Q3 2025 | PR Newswire |
| CoRegen | Develops regulatory T-cell therapies for aggressive solid tumors. | $93.39M | Q3 2025 | BioSpace |
| Gallant | Develops ready-to-use stem cell therapies for pets. | $18.0M | Q2 2025 | PR Newswire |
| Celltrio | Builds automated cell culture systems for cell and gene therapy manufacturing. | $15.0M | Q2 2025 | Business Wire |
| Kincell Bio | Provides manufacturing and development services for cell therapy companies. | $22.0M | Q2 2025 | Kincell Bio |
| Grove Biopharma | Develops hybrid biological and synthetic medicines for difficult intracellular disease targets. | $30.0M | Q2 2025 | Business Wire |
| RegCell | Develops regulatory T-cell reprogramming therapies for autoimmune disease and transplantation. | $8.5M | Q1 2025 | PR Newswire |
| Garuda Therapeutics | Develops ready-to-use blood stem cell therapies for severe blood disorders. | $50.0M | Q1 2025 | BioSpace |
| Aspect Biosystems | Develops bioprinted tissue therapies that replace, repair, or support damaged biological functions. | $115.0M | Q1 2025 | Aspect Biosystems |
| XyloCor Therapeutics | Develops one-time gene therapies that promote new blood vessel growth in heart disease. | $67.5M | Q1 2025 | Business Wire |
| GEMMABio | Develops gene therapies based on research from the University of Pennsylvania. | $34.0M | Q4 2024 | ASGCT Q4 Report |
| Tolerance Bio | Develops stem cell-derived therapies designed to restore immune tolerance. | $20.2M | Q4 2024 | ASGCT Q4 Report |
| Akamis Bio | Develops tumor-targeted viral gene therapies for cancer. | $60.0M | Q4 2024 | ASGCT Q4 Report |
| Celosia Therapeutics | Develops a gene therapy designed to slow or reverse motor neuron damage in ALS. | $16.75M | Q4 2024 | The Australian |
| Shift Bioscience | Develops gene-based treatments that aim to rejuvenate aging cells. | $16.0M | Q4 2024 | ASGCT Q4 Report |
| Somagenetix | Develops gene therapies using blood-forming stem cells. | $12.0M | Q4 2024 | ASGCT Q4 Report |
| Purespring Therapeutics | Develops AAV gene therapies for kidney diseases, including IgA nephropathy. | $105.0M | Q4 2024 | Syncona |
| Clock.bio | Studies stem cell rejuvenation to identify ways to reverse cellular aging. | $5.3M | Q4 2024 | ASGCT Q4 Report |
| Mirai Bio | Builds delivery, design, and manufacturing technology for gene therapies. | $50.0M | Q3 2024 | ASGCT Q3 Report |
| GC Therapeutics | Develops programmable stem cell-derived medicines for different diseases. | $65.0M | Q3 2024 | GC Therapeutics |
| Safi Biotherapeutics | Develops manufactured blood cell products for therapeutic use. | $5.0M | Q3 2024 | ASGCT Q3 Report |
| eGenesis | Develops genetically engineered animal organs for human transplantation. | $191.0M | Q3 2024 | eGenesis |
| Tern Therapeutics | Develops gene therapy programs for serious diseases. | $15.0M | Q3 2024 | ASGCT Q3 Report |
| Release Therapeutics | Develops cell-containing implants that deliver therapeutic proteins inside the body. | $3.8M | Q3 2024 | ASGCT Q3 Report |
| Amlogenyx | Develops gene therapies based on research from St. Jude Children's Research Hospital. | $14.0M | Q3 2024 | ASGCT Q3 Report |
| Oisin Biotechnologies | Develops DNA delivery technology for regenerative medicine and longevity treatments. | $15.0M | Q3 2024 | ASGCT Q3 Report |
| Cell BioEngines | Develops donor-derived cell therapy technologies. | $2.0M | Q3 2024 | ASGCT Q3 Report |
| Beacon Therapeutics | Develops gene therapies that aim to preserve or restore vision. | $170.0M | Q3 2024 | Beacon Therapeutics |
| Acorn Biolabs | Collects and preserves cells for possible future regenerative medicine treatments. | $8.0M | Q3 2024 | BetaKit |
| Exsilio Therapeutics | Develops therapies that insert therapeutic genes directly inside the body. | $82.0M | Q2 2024 | ASGCT Q2 Report |
| EpilepsyGTx | Develops gene therapy for people with treatment-resistant focal epilepsy. | $10.0M | Q2 2024 | ASGCT Q2 Report |
| Limula | Builds automated manufacturing systems for cell therapy production. | $6.9M | Q2 2024 | ASGCT Q2 Report |
| Latus Bio | Develops AAV gene therapies for diseases affecting the central nervous system. | $54.0M | Q2 2024 | Business Wire |
| Tempo Therapeutics | Develops tissue scaffolds for regenerative medicine and tissue repair. | $12.0M | Q1 2024 | PR Newswire |
| X-Therma | Develops preservation technology for organs, tissues, and cells. | $22.4M | Q1 2024 | X-Therma |
| Kenai Therapeutics | Develops donor-derived neuron replacement therapies for Parkinson's disease. | $82.0M | Q1 2024 | Kenai Therapeutics |
| Pelage Pharmaceuticals | Develops treatments that reactivate dormant hair follicle stem cells. | $16.75M | Q1 2024 | Pelage Pharmaceuticals |
| Neurona Therapeutics | Develops regenerative neuron therapies for epilepsy and other chronic neurological disorders. | $120.0M | Q1 2024 | Neurona Therapeutics |
| Tr1X | Develops donor-derived regulatory T-cell therapies for autoimmune and inflammatory diseases. | $75.0M | Q1 2024 | PR Newswire |
Related blog posts
- Who are the most valuable companies in the regenerative medicine market?
- How active is venture funding in the regenerative medicine market right now?
- Who has raised the most money in the regenerative medicine market?
- How are funding trends changing in the regenerative medicine market?
